Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRONNASDAQ:SDGRNASDAQ:TVTXNASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRONDisc Medicine$54.75+3.0%$49.35$30.82▼$68.73$1.90B0.76339,300 shs218,300 shsSDGRSchrodinger$20.96$22.66$16.60▼$28.47$1.55B1.58912,877 shs348,387 shsTVTXTravere Therapeutics$15.00+1.1%$16.72$7.72▼$25.29$1.33B0.721.62 million shs663,493 shsUPBUpstream Bio$11.20+0.6%$9.99$5.14▼$29.46$602.49MN/A352,911 shs212,087 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRONDisc Medicine+2.96%+1.14%+15.50%+32.81%+23.22%SDGRSchrodinger0.00%+2.29%-8.47%+16.25%+4.28%TVTXTravere Therapeutics+1.08%-0.86%-2.60%+0.07%+88.92%UPBUpstream Bio+0.63%+2.38%+3.32%+83.61%+1,119,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRONDisc Medicine3.0773 of 5 stars4.51.00.00.02.52.50.0SDGRSchrodinger2.8067 of 5 stars3.42.00.00.02.92.50.6TVTXTravere Therapeutics3.2055 of 5 stars4.43.00.00.01.80.80.6UPBUpstream Bio1.4181 of 5 stars3.50.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRONDisc Medicine 3.09Buy$96.7076.64% UpsideSDGRSchrodinger 2.75Moderate Buy$33.2558.64% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$32.14114.29% UpsideUPBUpstream Bio 3.00Buy$56.50404.46% UpsideCurrent Analyst Ratings BreakdownLatest UPB, IRON, TVTX, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$85.007/3/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.007/3/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$28.007/1/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$30.006/17/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.006/16/2025IRONDisc MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.006/11/2025IRONDisc MedicineRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$89.006/11/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$30.006/11/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $32.005/16/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/16/2025TVTXTravere TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRONDisc MedicineN/AN/AN/AN/A$14.85 per shareN/ASDGRSchrodinger$207.54M7.41N/AN/A$5.78 per share3.63TVTXTravere Therapeutics$233.18M5.71N/AN/A$0.76 per share19.74UPBUpstream Bio$2.37M254.20N/AN/A$8.77 per share1.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRONDisc Medicine-$109.36M-$3.92N/AN/AN/AN/A-22.61%-21.07%8/6/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)TVTXTravere Therapeutics-$321.55M-$2.81N/AN/AN/A-82.88%-1,179.73%-41.10%7/30/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/AN/AN/AN/A8/5/2025 (Estimated)Latest UPB, IRON, TVTX, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025SDGRSchrodinger-$0.83N/AN/AN/A$52.03 millionN/A5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A5/7/2025Q1 2025SDGRSchrodinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million5/6/2025Q1 2025UPBUpstream Bio-$0.49-$0.51-$0.02-$0.51$0.71 million$0.57 million5/1/2025Q1 2025TVTXTravere Therapeutics-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRONDisc MedicineN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRONDisc Medicine0.0437.6537.65SDGRSchrodingerN/A3.453.45TVTXTravere Therapeutics9.462.052.03UPBUpstream BioN/A47.4347.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRONDisc Medicine83.70%SDGRSchrodinger79.05%TVTXTravere TherapeuticsN/AUPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipIRONDisc Medicine4.24%SDGRSchrodinger8.60%TVTXTravere Therapeutics4.19%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRONDisc Medicine3034.63 million33.17 millionNot OptionableSDGRSchrodinger79073.38 million67.07 millionOptionableTVTXTravere Therapeutics46088.81 million85.08 millionOptionableUPBUpstream Bio3853.79 million46.50 millionN/AUPB, IRON, TVTX, and SDGR HeadlinesRecent News About These CompaniesUPB Upstream Bio, Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comUpstream Bio (NASDAQ:UPB) Trading 7.8% Higher - Should You Buy?June 20, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Shares Gap Down - What's Next?June 18, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Trading Down 3.4% - Here's What HappenedJune 16, 2025 | marketbeat.comUpstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody SpaceJune 16, 2025 | tipranks.comUpstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher PotencyJune 15, 2025 | msn.comUpstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI CongressJune 15, 2025 | quiverquant.comQTranslational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP ReceptorJune 15, 2025 | globenewswire.comUpstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street ZenJune 6, 2025 | marketbeat.comUpstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025June 5, 2025 | quiverquant.comQUpstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025June 5, 2025 | globenewswire.comUpstream Bio (NASDAQ:UPB) Trading Down 3.4% - Should You Sell?June 4, 2025 | marketbeat.comUpstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.comUpstream Bio names new chief technology officerMay 21, 2025 | investing.comUpstream Bio Appoints Stacy Price As CTOMay 21, 2025 | nasdaq.comUpstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical OperationsMay 21, 2025 | nasdaq.comUpstream Bio Appoints Stacy Price as Chief Technology OfficerMay 20, 2025 | globenewswire.comUpstream Bio Advances Verekitug in Clinical TrialsMay 7, 2025 | tipranks.comUpstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial PositionMay 6, 2025 | tipranks.comUpstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical ProgramsMay 6, 2025 | globenewswire.comUpstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is ImminentApril 17, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Tech Stocks You Can't Miss in This Market CycleBy Gabriel Osorio-Mazilli | June 17, 2025View 3 Tech Stocks You Can't Miss in This Market CycleWhiplash for Investors: AeroVironment's Confusing Stock SignalsBy Jeffrey Neal Johnson | July 2, 2025View Whiplash for Investors: AeroVironment's Confusing Stock SignalsAeroVironment Will Hit New Highs This Year: Bull Flag ConfirmedBy Thomas Hughes | June 25, 2025View AeroVironment Will Hit New Highs This Year: Bull Flag ConfirmedUPB, IRON, TVTX, and SDGR Company DescriptionsDisc Medicine NASDAQ:IRON$54.74 +1.58 (+2.96%) Closing price 07/3/2025 01:04 PM EasternExtended Trading$54.74 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Schrodinger NASDAQ:SDGR$20.96 0.00 (0.00%) Closing price 07/3/2025 03:29 PM EasternExtended Trading$21.04 +0.08 (+0.38%) As of 07/3/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Travere Therapeutics NASDAQ:TVTX$15.00 +0.16 (+1.08%) Closing price 07/3/2025 01:04 PM EasternExtended Trading$15.00 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Upstream Bio NASDAQ:UPB$11.20 +0.07 (+0.63%) As of 07/3/2025 01:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
